Frontpage Hero

Because we care, we need to act

Annual and Sustainability Report

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.

Annual General Meeting 2018

The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
Sobi Annual General Meeting

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the third quarter 2018. Total revenues grew 45 per cent compared with Q3 2017 (34 per cent at constant exchange rates (CER)) and amounted to SEK 2,315 M. EBITA was SEK 933 M, an increase of 74...

10/31/2018 - 08:00

On 31 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same...

10/23/2018 - 10:30

Sobi™ Cycle bike ride from Mainz to Brussels raises funds, awareness for haemophilia

A team of cyclists from Sobi™ have biked from Mainz to Brussels 2-4 October to help raise funds for people with haemophilia as well as awareness about the condition.

SobiCycle 2018 is...

10/04/2018 - 14:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) releases the primary efficacy results from the phase 2 study with anakinra in patients with acute gout – the anaGO study. For the primary endpoint of patient assessed pain intensity in the most affected joint there was a...

10/03/2018 - 08:00
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden